0	0	1998-09-22	CD	O	O	B-Num
0	1	09	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	36	CD	O	B-NP	I-Num
0	4	THE	DT	O	B-NP	B-Org
0	5	PSA	NNP	O	I-NP	I-Org
0	6	TEST	NNP	O	I-NP	I-Org
0	7	HAS	VBZ	O	B-VP	I-Org
0	8	REVOLUTIONIZED	NNP	O	O	I-Org
0	9	PROSTATE	NNP	O	O	I-Org
0	10	MEDICINE	NNP	O	O	I-Org

1	0	WASHINGTON	NNP	O	O	B-LocStat
1	1	_	NN	O	B-VP	O
1	2	A	DT	O	B-NP	O
1	3	simple	JJ	O	I-NP	O
1	4	blood	NN	O	I-NP	O
1	5	test	NN	O	I-NP	O
1	6	has	VBZ	O	B-VP	O
1	7	revolutionized	VBD	O	I-VP	O
1	8	prostate	NN	O	B-NP	B-Jour
1	9	medicine	NN	O	I-NP	B-Medical
1	10	by	IN	O	B-PP	O
1	11	diagnosing	VBG	O	B-VP	O
1	12	thousands	NNS	O	B-NP	B-Num
1	13	of	IN	O	B-PP	O
1	14	new	JJ	O	B-NP	O
1	15	cases	NNS	O	I-NP	O
1	16	of	IN	O	B-PP	O
1	17	prostate	NN	O	B-NP	B-Jour
1	18	cancer	NN	O	I-NP	B-Medical
1	19	every	DT	O	B-NP	O
1	20	year	NN	O	I-NP	O
1	21	in	IN	O	B-PP	O
1	22	men	NNS	O	B-NP	O
1	23	who	WP	O	B-NP	O
1	24	have	VBP	O	B-VP	O
1	25	few	JJ	O	O	O
1	26	COMMA	COMMA	O	O	O
1	27	if	IN	O	O	O
1	28	any	DT	O	B-NP	O
1	29	COMMA	COMMA	O	O	O
1	30	outward	RB	O	O	O
1	31	symptoms	NNS	O	B-NP	O
1	32	.	.	O	O	O

2	0	Before	IN	O	B-PP	O
2	1	the	DT	O	B-NP	O
2	2	prostate-specific	JJ	O	I-NP	O
2	3	antigen	NN	O	I-NP	B-Medical
2	4	-LBR-	-LBR-	O	O	O
2	5	PSA	NNP	O	O	O
2	6	-RBR-	-RBR-	O	O	O
2	7	test	NN	O	B-NP	O
2	8	came	VBD	O	B-VP	O
2	9	into	IN	O	B-PP	O
2	10	widespread	JJ	O	B-NP	O
2	11	use	NN	O	I-NP	O
2	12	in	IN	O	B-PP	O
2	13	the	DT	O	B-NP	O
2	14	early	JJ	O	I-NP	O
2	15	1990s	CD	O	I-NP	B-Date
2	16	COMMA	COMMA	O	O	O
2	17	an	DT	O	B-NP	O
2	18	examining	VBG	O	I-NP	O
2	19	physician	NN	O	I-NP	B-ProfTitle
2	20	would	MD	O	B-VP	O
2	21	rely	VB	O	I-VP	O
2	22	on	IN	O	B-PP	O
2	23	a	DT	O	B-NP	O
2	24	finger	NN	O	I-NP	O
2	25	exam	NN	O	O	O
2	26	_	NN	O	B-VP	O
2	27	a	DT	O	B-NP	O
2	28	digital	JJ	O	I-NP	O
2	29	rectal	JJ	O	I-NP	B-Medical
2	30	examination	NN	O	I-NP	O
2	31	-LBR-	-LBR-	O	O	O
2	32	DRE	NNP	O	O	B-OrgCorp
2	33	-RBR-	-RBR-	O	O	O
2	34	_	NN	O	B-NP	O
2	35	to	TO	O	B-VP	O
2	36	feel	VB	O	I-VP	O
2	37	for	IN	O	B-PP	O
2	38	prostate	NN	O	B-NP	B-Jour
2	39	tumors	NNS	O	I-NP	O
2	40	through	IN	O	B-PP	O
2	41	the	DT	O	B-NP	O
2	42	wall	NN	O	I-NP	O
2	43	of	IN	O	B-PP	O
2	44	the	DT	O	B-NP	O
2	45	rectum	NN	O	I-NP	O
2	46	.	.	O	O	O

3	0	This	DT	O	B-NP	O
3	1	technique	NN	O	I-NP	O
3	2	meant	VBD	O	B-VP	O
3	3	that	IN	O	O	O
3	4	most	JJS	O	B-NP	O
3	5	men	NNS	O	I-NP	O
3	6	were	VBD	O	B-VP	O
3	7	diagnosed	VBN	O	I-VP	O
3	8	in	IN	O	B-PP	O
3	9	the	DT	O	B-NP	O
3	10	later	JJR	O	I-NP	O
3	11	stages	VBZ	O	I-NP	O
3	12	of	IN	O	B-PP	O
3	13	the	DT	O	B-NP	O
3	14	disease	NN	O	I-NP	B-Medical
3	15	when	WRB	O	O	O
3	16	a	DT	O	B-NP	O
3	17	cure	NN	O	I-NP	O
3	18	is	VBZ	O	B-VP	O
3	19	difficult	JJ	O	O	O
3	20	.	.	O	O	O

4	0	The	DT	O	B-NP	O
4	1	PSA	NNP	O	I-NP	B-Org
4	2	test	NN	O	I-NP	O
4	3	makes	VBZ	O	B-VP	O
4	4	it	PRP	O	B-NP	O
4	5	possible	JJ	O	O	O
4	6	to	TO	O	B-VP	O
4	7	detect	VB	O	I-VP	O
4	8	tumors	NNS	O	B-NP	O
4	9	before	IN	O	O	O
4	10	they	PRP	O	B-NP	O
4	11	grow	VBP	O	B-VP	O
4	12	so	RB	O	O	O
4	13	large	JJ	O	O	O
4	14	that	IN	O	O	O
4	15	they	PRP	O	B-NP	O
4	16	can	MD	O	B-VP	O
4	17	be	VB	O	I-VP	O
4	18	felt	VBN	O	I-VP	O
4	19	during	IN	O	B-PP	O
4	20	a	DT	O	B-NP	O
4	21	DRE	NNP	O	I-NP	B-OrgCorp
4	22	.	.	O	O	O

5	0	About	IN	O	B-NP	O
5	1	10	CD	O	I-NP	B-Num
5	2	million	CD	O	I-NP	B-Num
5	3	PSA	NNP	O	I-NP	O
5	4	blood	NN	O	I-NP	O
5	5	tests	NNS	O	I-NP	O
5	6	are	VBP	O	B-VP	O
5	7	performed	VBN	O	I-VP	O
5	8	annually	RB	O	O	O
5	9	COMMA	COMMA	O	O	O
5	10	according	VBG	O	B-PP	O
5	11	to	TO	O	B-PP	O
5	12	Dr.	NNP	O	B-NP	B-ProfTitle
5	13	William	NNP	O	I-NP	B-Peop
5	14	Catalona	NNP	O	I-NP	I-Peop
5	15	COMMA	COMMA	O	O	O
5	16	director	NN	O	B-NP	B-ProfTitle
5	17	of	IN	O	B-PP	O
5	18	urologic	JJ	O	B-NP	O
5	19	surgery	NN	O	I-NP	O
5	20	at	IN	O	B-PP	O
5	21	Washington	NNP	O	B-NP	B-OrgUniv
5	22	University	NNP	O	I-NP	I-OrgUniv
5	23	School	NNP	O	I-NP	I-OrgUniv
5	24	of	IN	O	B-PP	O
5	25	Medicine	NNP	O	B-NP	O
5	26	in	IN	O	B-PP	O
5	27	St.	NNP	O	B-NP	B-LocCit
5	28	Louis	NNP	O	I-NP	I-LocCit
5	29	and	CC	O	O	O
5	30	one	CD	O	B-NP	B-Num
5	31	of	IN	O	B-PP	O
5	32	the	DT	O	B-NP	O
5	33	inventors	NNS	O	I-NP	O
5	34	of	IN	O	B-PP	O
5	35	the	DT	O	B-NP	O
5	36	test	NN	O	I-NP	O
5	37	.	.	O	O	O

6	0	``	``	O	O	O
6	1	We	PRP	O	B-NP	O
6	2	are	VBP	O	B-VP	O
6	3	now	RB	O	I-VP	O
6	4	seeing	VBG	O	I-VP	O
6	5	earlier	RBR	O	O	O
6	6	and	CC	O	O	O
6	7	earlier	RBR	O	O	O
6	8	tumorsCOMMA	NN	O	O	O
6	9	''	''	O	O	O
6	10	said	VBD	O	B-VP	O
6	11	Catalona	NNP	O	B-NP	B-Peop
6	12	.	.	O	O	O

7	0	The	DT	O	B-NP	O
7	1	test	NN	O	I-NP	O
7	2	measures	VBZ	O	B-VP	O
7	3	a	DT	O	B-NP	O
7	4	protein	NN	O	I-NP	B-Medical
7	5	produced	VBD	O	B-VP	O
7	6	by	IN	O	B-PP	O
7	7	epithelial	JJ	O	B-NP	O
7	8	cells	NNS	O	I-NP	O
7	9	within	IN	O	B-PP	O
7	10	the	DT	O	B-NP	O
7	11	prostate	NN	O	I-NP	B-Jour
7	12	.	.	O	O	O

8	0	A	DT	O	B-NP	O
8	1	healthy	JJ	O	I-NP	O
8	2	man	NN	O	I-NP	O
8	3	should	MD	O	B-VP	O
8	4	have	VB	O	I-VP	O
8	5	virtually	RB	O	B-NP	O
8	6	undetectable	JJ	O	I-NP	O
8	7	levels	NNS	O	I-NP	O
8	8	of	IN	O	B-PP	O
8	9	the	DT	O	B-NP	O
8	10	protein	NN	O	I-NP	B-Medical
8	11	.	.	O	O	O

9	0	However	RB	O	O	O
9	1	COMMA	COMMA	O	O	O
9	2	more	RBR	O	O	O
9	3	of	IN	O	B-PP	O
9	4	these	DT	O	B-NP	O
9	5	cells	NNS	O	I-NP	O
9	6	are	VBP	O	B-VP	O
9	7	produced	VBN	O	I-VP	O
9	8	when	WRB	O	O	O
9	9	the	DT	O	B-NP	O
9	10	body	NN	O	I-NP	O
9	11	is	VBZ	O	B-VP	O
9	12	fighting	VBG	O	I-VP	B-Sport
9	13	off	IN	O	B-PP	O
9	14	a	DT	O	B-NP	O
9	15	prostate	NN	O	I-NP	B-Jour
9	16	infection	NN	O	I-NP	B-Medical
9	17	COMMA	COMMA	O	O	O
9	18	thereby	RB	O	O	O
9	19	increasing	VBG	O	B-VP	O
9	20	the	DT	O	B-NP	O
9	21	protein	NN	O	I-NP	B-Medical
9	22	level	NN	O	I-NP	O
9	23	.	.	O	O	O

10	0	Similarly	RB	O	O	O
10	1	COMMA	COMMA	O	O	O
10	2	the	DT	O	B-NP	O
10	3	protein	NN	O	I-NP	B-Medical
10	4	level	NN	O	I-NP	O
10	5	may	MD	O	B-VP	O
10	6	shoot	VB	O	I-VP	O
10	7	up	IN	O	O	O
10	8	if	IN	O	O	O
10	9	the	DT	O	B-NP	O
10	10	epithelial	JJ	O	I-NP	O
10	11	cells	NNS	O	I-NP	O
10	12	turn	VBP	O	B-VP	O
10	13	malignant	JJ	O	O	B-Medical
10	14	and	CC	O	O	O
10	15	COMMA	COMMA	O	O	O
10	16	as	IN	O	O	O
10	17	cancers	NNS	O	B-NP	O
10	18	do	VBP	O	B-VP	O
10	19	COMMA	COMMA	O	O	O
10	20	multiply	VBP	O	B-VP	O
10	21	out	IN	O	O	O
10	22	of	IN	O	B-PP	O
10	23	control	NN	O	B-NP	O
10	24	.	.	O	O	O

11	0	``	``	O	O	O
11	1	Elevated	NNP	O	B-NP	O
11	2	PSA	NNP	O	I-NP	O
11	3	is	VBZ	O	B-VP	O
11	4	related	VBN	O	I-VP	O
11	5	to	TO	O	B-PP	O
11	6	an	DT	O	B-NP	O
11	7	abnormal	JJ	O	I-NP	O
11	8	proliferation	NN	O	I-NP	B-Medical
11	9	of	IN	O	B-PP	O
11	10	certain	JJ	O	B-NP	O
11	11	prostate	NN	O	I-NP	B-Jour
11	12	cells	NNS	O	I-NP	O
11	13	COMMA	COMMA	O	O	O
11	14	epithelial	JJ	O	O	O
11	15	only	RB	O	O	O
11	16	COMMA	COMMA	O	O	O
11	17	whether	IN	O	O	O
11	18	benign	JJ	O	B-NP	B-Medical
11	19	or	CC	O	I-NP	O
11	20	malignantCOMMA	NN	O	I-NP	O
11	21	''	''	O	O	O
11	22	said	VBD	O	B-VP	O
11	23	Dr.	NNP	O	B-NP	B-ProfTitle
11	24	Michael	NNP	O	I-NP	B-Peop
11	25	Manyak	NNP	O	I-NP	I-Peop
11	26	COMMA	COMMA	O	O	O
11	27	chairman	NN	O	B-NP	O
11	28	of	IN	O	B-PP	O
11	29	the	DT	O	B-NP	O
11	30	urology	NN	O	I-NP	B-Jour
11	31	department	NN	O	I-NP	O
11	32	at	IN	O	B-PP	O
11	33	George	NNP	O	B-NP	B-OrgUniv
11	34	Washington	NNP	O	I-NP	I-OrgUniv
11	35	University	NNP	O	I-NP	I-OrgUniv
11	36	Medical	NNP	O	I-NP	B-OrgCorp
11	37	Center	NNP	O	I-NP	B-LocStruct
11	38	in	IN	O	B-PP	O
11	39	Washington	NNP	O	B-NP	B-LocCit
11	40	COMMA	COMMA	O	O	O
11	41	D.C	NNP	O	B-NP	B-Loc
11	42	.	.	O	O	O

12	0	The	DT	O	O	O
12	1	protein	NN	O	O	B-Medical
12	2	seeps	NN	O	O	O
12	3	into	IN	O	B-PP	O
12	4	the	DT	O	B-NP	O
12	5	blood	NN	O	I-NP	O
12	6	and	CC	O	O	O
12	7	thus	RB	O	O	O
12	8	can	MD	O	B-VP	O
12	9	be	VB	O	I-VP	O
12	10	detected	VBN	O	I-VP	O
12	11	in	IN	O	B-PP	O
12	12	a	DT	O	B-NP	O
12	13	blood	NN	O	I-NP	O
12	14	test	NN	O	I-NP	O
12	15	.	.	O	O	O

13	0	Results	NNS	O	B-NP	O
13	1	under	IN	O	B-PP	O
13	2	4	CD	O	B-NP	B-Num
13	3	nanograms	NNS	O	I-NP	O
13	4	per	IN	O	B-PP	O
13	5	milliliter	NN	O	B-NP	O
13	6	-LBR-	-LBR-	O	O	O
13	7	ng/ml	NN	O	O	O
13	8	-RBR-	-RBR-	O	O	O
13	9	are	VBP	O	B-VP	O
13	10	considered	VBN	O	I-VP	O
13	11	normal	JJ	O	O	O
13	12	COMMA	COMMA	O	O	O
13	13	while	IN	O	O	O
13	14	those	DT	O	B-NP	O
13	15	over	IN	O	B-PP	O
13	16	10	CD	O	O	B-Num
13	17	ng/ml	NN	O	O	O
13	18	suggest	VBP	O	B-VP	O
13	19	a	DT	O	B-NP	O
13	20	problem	NN	O	I-NP	O
13	21	.	.	O	O	O

14	0	Values	NNP	O	B-NP	O
14	1	between	IN	O	B-PP	O
14	2	4	CD	O	B-NP	B-Num
14	3	and	CC	O	I-NP	O
14	4	10	CD	O	I-NP	B-Num
14	5	are	VBP	O	B-VP	O
14	6	borderline	NN	O	B-NP	O
14	7	.	.	O	O	O

15	0	If	IN	O	O	O
15	1	the	DT	O	B-NP	O
15	2	test	NN	O	I-NP	O
15	3	result	NN	O	I-NP	O
15	4	is	VBZ	O	B-VP	O
15	5	10	CD	O	B-NP	B-Num
15	6	or	CC	O	I-NP	O
15	7	higher	JJR	O	I-NP	O
15	8	and	CC	O	O	O
15	9	the	DT	O	B-NP	O
15	10	patient	NN	O	I-NP	B-Medical
15	11	is	VBZ	O	B-VP	O
15	12	not	RB	O	O	O
15	13	elderly	JJ	O	O	O
15	14	COMMA	COMMA	O	O	O
15	15	doctors	NNS	O	B-NP	B-ProfTitle
15	16	will	MD	O	B-VP	O
15	17	recommend	VB	O	I-VP	O
15	18	more	RBR	O	B-NP	O
15	19	sophisticated	JJ	O	I-NP	O
15	20	diagnostic	JJ	O	I-NP	O
15	21	tests	NNS	O	I-NP	O
15	22	COMMA	COMMA	O	O	O
15	23	including	VBG	O	B-PP	O
15	24	a	DT	O	B-NP	O
15	25	six-needle	NN	O	I-NP	O
15	26	biopsy	NN	O	I-NP	B-Medical
15	27	of	IN	O	B-PP	O
15	28	the	DT	O	B-NP	O
15	29	prostate	NN	O	I-NP	B-Jour
15	30	.	.	O	O	O

16	0	Urologists	NNPS	O	B-NP	O
16	1	may	MD	O	B-VP	O
16	2	recommend	VB	O	I-VP	O
16	3	biopsies	NNS	O	B-NP	O
16	4	for	IN	O	B-PP	O
16	5	borderline	NN	O	B-NP	O
16	6	PSA	NNP	O	I-NP	O
16	7	readings	NNS	O	I-NP	O
16	8	COMMA	COMMA	O	O	O
16	9	depending	VBG	O	B-PP	O
16	10	on	IN	O	B-PP	O
16	11	the	DT	O	B-NP	O
16	12	results	NNS	O	I-NP	O
16	13	of	IN	O	B-PP	O
16	14	the	DT	O	B-NP	O
16	15	DRE	NNP	O	I-NP	B-OrgCorp
16	16	COMMA	COMMA	O	O	O
16	17	what	WP	O	B-NP	O
16	18	an	DT	O	B-NP	O
16	19	ultrasound	NN	O	I-NP	O
16	20	scan	NN	O	I-NP	O
16	21	of	IN	O	B-PP	O
16	22	the	DT	O	B-NP	O
16	23	gland	NN	O	I-NP	O
16	24	reveals	VBZ	O	B-VP	O
16	25	COMMA	COMMA	O	O	O
16	26	how	WRB	O	O	O
16	27	fast	RB	O	O	O
16	28	the	DT	O	B-NP	O
16	29	PSA	NNP	O	I-NP	O
16	30	level	NN	O	I-NP	O
16	31	is	VBZ	O	B-VP	O
16	32	rising	VBG	O	I-VP	O
16	33	and	CC	O	O	O
16	34	the	DT	O	B-NP	O
16	35	patient	NN	O	I-NP	B-Medical
16	36	's	POS	O	B-NP	O
16	37	age	NN	O	I-NP	O
16	38	.	.	O	O	O

17	0	The	DT	O	B-NP	O
17	1	PSA	NNP	O	I-NP	B-Org
17	2	test	NN	O	I-NP	O
17	3	misses	VBZ	O	B-VP	O
17	4	about	IN	O	B-NP	O
17	5	25	CD	O	I-NP	B-NumPercent
17	6	percent	NN	O	I-NP	I-NumPercent
17	7	of	IN	O	B-PP	O
17	8	cancers	NNS	O	B-NP	O
17	9	COMMA	COMMA	O	O	O
17	10	so	IN	O	O	O
17	11	a	DT	O	B-NP	O
17	12	normal	JJ	O	I-NP	O
17	13	PSA	NNP	O	I-NP	O
17	14	can	MD	O	B-VP	O
17	15	give	VB	O	I-VP	O
17	16	false	JJ	O	B-NP	O
17	17	reassurance	NN	O	I-NP	O
17	18	that	IN	O	O	O
17	19	cancer	NN	O	B-NP	B-Medical
17	20	is	VBZ	O	B-VP	O
17	21	not	RB	O	O	O
17	22	present	JJ	O	O	O
17	23	.	.	O	O	O

18	0	The	DT	O	B-NP	O
18	1	test	NN	O	I-NP	O
18	2	also	RB	O	O	O
18	3	may	MD	O	B-VP	O
18	4	provide	VB	O	I-VP	O
18	5	high	JJ	O	B-NP	O
18	6	readings	NNS	O	I-NP	O
18	7	for	IN	O	B-PP	O
18	8	such	JJ	O	B-NP	O
18	9	non-cancerous	JJ	O	I-NP	O
18	10	conditions	NNS	O	I-NP	O
18	11	as	IN	O	B-PP	O
18	12	enlargement	NN	O	B-NP	O
18	13	of	IN	O	B-PP	O
18	14	the	DT	O	B-NP	O
18	15	prostate	NN	O	I-NP	B-Jour
18	16	or	CC	O	O	O
18	17	a	DT	O	B-NP	O
18	18	common	JJ	O	I-NP	O
18	19	prostate	NN	O	I-NP	B-Jour
18	20	infection	NN	O	I-NP	B-Medical
18	21	known	VBN	O	B-VP	O
18	22	as	IN	O	B-PP	O
18	23	prostatitis	NN	O	B-NP	B-Medical
18	24	.	.	O	O	O

19	0	Because	IN	O	O	O
19	1	the	DT	O	B-NP	O
19	2	PSA	NNP	O	I-NP	O
19	3	test	NN	O	I-NP	O
19	4	can	MD	O	B-VP	O
19	5	't	NN	O	I-VP	O
19	6	distinguish	VB	O	I-VP	O
19	7	between	IN	O	B-PP	O
19	8	cancer	NN	O	B-NP	B-Medical
19	9	and	CC	O	O	O
19	10	benign	JJ	O	B-NP	B-Medical
19	11	afflictions	NNS	O	I-NP	O
19	12	COMMA	COMMA	O	O	O
19	13	many	JJ	O	B-NP	O
19	14	men	NNS	O	I-NP	O
19	15	with	IN	O	B-PP	O
19	16	a	DT	O	B-NP	O
19	17	high	JJ	O	I-NP	O
19	18	PSA	NNP	O	I-NP	O
19	19	will	MD	O	B-VP	O
19	20	not	RB	O	I-VP	O
19	21	have	VB	O	I-VP	O
19	22	cancer	NN	O	B-NP	B-Medical
19	23	when	WRB	O	O	O
19	24	biopsied	JJ	O	O	O
19	25	.	.	O	O	O

20	0	The	DT	O	B-NP	O
20	1	PSA	NNP	O	I-NP	O
20	2	also	RB	O	O	O
20	3	can	MD	O	B-VP	O
20	4	't	NN	O	I-VP	O
20	5	distinguish	VB	O	I-VP	O
20	6	between	IN	O	B-PP	O
20	7	slow-growing	JJ	O	B-NP	O
20	8	and	CC	O	I-NP	O
20	9	fast-moving	JJ	O	I-NP	O
20	10	cancers	NNS	O	I-NP	O
20	11	.	.	O	O	O

21	0	Meanwhile	RB	O	O	O
21	1	COMMA	COMMA	O	O	O
21	2	researchers	NNS	O	B-NP	B-ProfTitle
21	3	are	VBP	O	B-VP	O
21	4	developing	VBG	O	I-VP	O
21	5	more	RBR	O	B-NP	O
21	6	accurate	JJ	O	I-NP	O
21	7	tests	NNS	O	I-NP	O
21	8	.	.	O	O	O

22	0	_	NN	O	O	O
22	1	The	DT	O	B-NP	O
22	2	Food	NNP	O	I-NP	B-Food
22	3	and	CC	O	I-NP	O
22	4	Drug	NNP	O	I-NP	O
22	5	Administration	NNP	O	I-NP	O
22	6	in	IN	O	B-PP	O
22	7	March	NNP	O	B-NP	B-Date
22	8	approved	VBD	O	B-VP	O
22	9	a	DT	O	B-NP	O
22	10	new	JJ	O	I-NP	O
22	11	test	NN	O	I-NP	O
22	12	for	IN	O	B-PP	O
22	13	patients	NNS	O	B-NP	O
22	14	with	IN	O	B-PP	O
22	15	abnormal	JJ	O	B-NP	O
22	16	PSA	NNP	O	I-NP	B-Org
22	17	readings	NNS	O	I-NP	O
22	18	.	.	O	O	O

23	0	While	IN	O	O	O
23	1	the	DT	O	B-NP	O
23	2	traditional	JJ	O	I-NP	O
23	3	PSA	NNP	O	I-NP	B-Org
23	4	test	NN	O	I-NP	O
23	5	measures	VBZ	O	B-VP	O
23	6	the	DT	O	B-NP	O
23	7	protein	NN	O	I-NP	B-Medical
23	8	when	WRB	O	O	O
23	9	it	PRP	O	B-NP	O
23	10	is	VBZ	O	O	O
23	11	bound	VBN	O	O	O
23	12	chemically	RB	O	O	O
23	13	to	TO	O	B-PP	O
23	14	the	DT	O	B-NP	O
23	15	compound	NN	O	I-NP	O
23	16	alpa1-antichymotrypsin	NN	O	I-NP	O
23	17	or	CC	O	I-NP	O
23	18	alpha2-macroglobulin	NN	O	I-NP	O
23	19	COMMA	COMMA	O	O	O
23	20	the	DT	O	B-NP	O
23	21	new	JJ	O	I-NP	O
23	22	test	NN	O	I-NP	O
23	23	measures	NNS	O	I-NP	O
23	24	levels	NNS	O	I-NP	O
23	25	of	IN	O	B-PP	O
23	26	``	``	O	B-NP	O
23	27	free	JJ	O	I-NP	O
23	28	''	''	O	I-NP	O
23	29	PSA	NNP	O	I-NP	B-Peop
23	30	COMMA	COMMA	O	O	O
23	31	not	RB	O	O	O
23	32	bound	VBN	O	O	O
23	33	to	TO	O	B-PP	O
23	34	these	DT	O	B-NP	O
23	35	substances	NNS	O	I-NP	O
23	36	.	.	O	O	O

24	0	Men	NNS	O	B-NP	O
24	1	with	IN	O	B-PP	O
24	2	prostate	NN	O	B-NP	B-Jour
24	3	cancer	NN	O	I-NP	B-Medical
24	4	have	VBP	O	B-VP	O
24	5	less	JJR	O	B-NP	O
24	6	``	``	O	I-NP	O
24	7	free	JJ	O	I-NP	O
24	8	PSA	NNP	O	I-NP	O
24	9	''	''	O	O	O
24	10	than	IN	O	B-PP	O
24	11	men	NNS	O	B-NP	O
24	12	who	WP	O	B-NP	O
24	13	have	VBP	O	B-VP	O
24	14	benign	JJ	O	B-NP	B-Medical
24	15	conditions	NNS	O	I-NP	O
24	16	.	.	O	O	O

25	0	The	DT	O	O	O
25	1	lower	JJR	O	O	O
25	2	the	DT	O	B-NP	O
25	3	percentage	NN	O	I-NP	O
25	4	of	IN	O	B-PP	O
25	5	free	JJ	O	B-NP	O
25	6	PSA	NNP	O	I-NP	O
25	7	COMMA	COMMA	O	O	O
25	8	the	DT	O	O	O
25	9	higher	JJR	O	O	O
25	10	the	DT	O	B-NP	O
25	11	likelihood	NN	O	I-NP	O
25	12	of	IN	O	B-PP	O
25	13	cancer	NN	O	B-NP	B-Medical
25	14	.	.	O	O	O

26	0	The	DT	O	B-NP	O
26	1	test	NN	O	I-NP	O
26	2	's	POS	O	B-NP	O
26	3	manufacturers	NNS	O	I-NP	B-ProfTitle
26	4	claim	VBP	O	B-VP	O
26	5	it	PRP	O	B-NP	O
26	6	could	MD	O	B-VP	O
26	7	eliminate	VB	O	I-VP	O
26	8	120COMMA000	CD	O	B-NP	B-Num
26	9	needless	JJ	O	I-NP	O
26	10	biopsies	NNS	O	I-NP	O
26	11	a	DT	O	B-NP	O
26	12	year	NN	O	I-NP	O
26	13	.	.	O	O	O

27	0	_	NN	O	O	O
27	1	The	DT	O	B-NP	O
27	2	Pacific	NNP	O	I-NP	O
27	3	Northwest	NNP	O	I-NP	B-Org
27	4	Cancer	NNP	O	I-NP	I-Org
27	5	Foundation	NNP	O	I-NP	I-Org
27	6	in	IN	O	B-PP	O
27	7	Seattle	NNP	O	B-NP	B-LocCit
27	8	is	VBZ	O	B-VP	O
27	9	developing	VBG	O	I-VP	O
27	10	a	DT	O	B-NP	O
27	11	blood	NN	O	I-NP	O
27	12	test	NN	O	I-NP	O
27	13	based	VBN	O	O	O
27	14	on	IN	O	B-PP	O
27	15	the	DT	O	B-NP	O
27	16	PSA	NNP	O	I-NP	O
27	17	that	WDT	O	B-NP	O
27	18	will	MD	O	B-VP	O
27	19	help	VB	O	I-VP	O
27	20	determine	VB	O	I-VP	O
27	21	whether	IN	O	O	O
27	22	a	DT	O	B-NP	O
27	23	cancer	NN	O	I-NP	B-Medical
27	24	is	VBZ	O	B-VP	O
27	25	aggressive	JJ	O	O	O
27	26	and	CC	O	O	O
27	27	life	NN	O	O	O
27	28	threatening	VBG	O	B-VP	O
27	29	or	CC	O	I-VP	O
27	30	only	RB	O	I-VP	O
27	31	growing	VBG	O	I-VP	O
27	32	slowly	RB	O	O	O
27	33	.	.	O	O	O

28	0	_	NN	O	O	O
28	1	The	DT	O	B-NP	O
28	2	Memorial	NNP	O	I-NP	B-OrgCorp
28	3	Sloan-Kettering	NNP	O	I-NP	I-OrgCorp
28	4	Cancer	NNP	O	I-NP	I-OrgCorp
28	5	Center	NNP	O	I-NP	I-OrgCorp
28	6	and	CC	O	O	I-OrgCorp
28	7	the	DT	O	B-NP	I-OrgCorp
28	8	Howard	NNP	O	I-NP	I-OrgCorp
28	9	Hughes	NNP	O	I-NP	I-OrgCorp
28	10	Medical	NNP	O	I-NP	I-OrgCorp
28	11	Institute	NNP	O	I-NP	I-OrgCorp
28	12	in	IN	O	B-PP	O
28	13	New	NNP	O	B-NP	B-LocCit
28	14	York	NNP	O	I-NP	I-LocCit
28	15	are	VBP	O	B-VP	O
28	16	researching	VBG	O	I-VP	O
28	17	whether	IN	O	O	O
28	18	the	DT	O	B-NP	O
28	19	presence	NN	O	I-NP	O
28	20	of	IN	O	B-PP	O
28	21	a	DT	O	B-NP	O
28	22	certain	JJ	O	I-NP	O
28	23	protein	NN	O	I-NP	B-Medical
28	24	in	IN	O	B-PP	O
28	25	the	DT	O	B-NP	O
28	26	blood	NN	O	I-NP	O
28	27	called	VBD	O	B-VP	O
28	28	p27	NN	O	B-NP	O
28	29	signals	NNS	O	I-NP	O
28	30	aggressive	JJ	O	B-NP	O
28	31	cancer	NN	O	I-NP	B-Medical
28	32	.	.	O	O	O

29	0	_	NN	O	O	O
29	1	The	DT	O	B-NP	O
29	2	Mayo	NNP	O	I-NP	B-Org
29	3	Clinic	NNP	O	I-NP	I-Org
29	4	in	IN	O	B-PP	O
29	5	Rochester	NNP	O	B-NP	B-LocCit
29	6	COMMA	COMMA	O	O	O
29	7	Minn.	NNP	O	B-NP	B-LocStat
29	8	COMMA	COMMA	O	O	O
29	9	is	VBZ	O	B-VP	O
29	10	working	VBG	O	I-VP	O
29	11	on	IN	O	B-PP	O
29	12	a	DT	O	B-NP	O
29	13	new	JJ	O	I-NP	O
29	14	test	NN	O	I-NP	O
29	15	that	IN	O	B-NP	O
29	16	measures	NNS	O	B-VP	O
29	17	a	DT	O	B-NP	O
29	18	protein	NN	O	I-NP	B-Medical
29	19	similar	JJ	O	O	O
29	20	to	TO	O	B-PP	O
29	21	PSA	NNP	O	B-NP	B-Org
29	22	called	VBD	O	B-VP	O
29	23	human	JJ	O	B-NP	B-Animal
29	24	glandular	JJ	O	I-NP	O
29	25	kallikrein	NN	O	I-NP	O
29	26	2	CD	O	I-NP	B-Num
29	27	COMMA	COMMA	O	O	O
29	28	or	CC	O	O	O
29	29	HK2	NNP	O	B-NP	B-Money
29	30	.	.	O	O	O

30	0	Researchers	NNS	O	B-NP	B-ProfTitle
30	1	believe	VBP	O	B-VP	O
30	2	that	IN	O	O	O
30	3	HK2	NNP	O	B-NP	B-Money
30	4	measurements	NNS	O	I-NP	O
30	5	will	MD	O	B-VP	O
30	6	tell	VB	O	I-VP	O
30	7	doctors	NNS	O	B-NP	B-ProfTitle
30	8	which	WDT	O	B-NP	O
30	9	men	NNS	O	B-NP	O
30	10	with	IN	O	B-PP	O
30	11	borderline	NN	O	B-NP	O
30	12	PSA	NNP	O	I-NP	O
30	13	values	NNS	O	I-NP	O
30	14	actually	RB	O	O	O
30	15	have	VBP	O	B-VP	O
30	16	cancer	NN	O	B-NP	B-Medical
30	17	.	.	O	O	O

31	0	Catalona	NNP	O	B-NP	B-Peop
31	1	said	VBD	O	B-VP	O
31	2	that	IN	O	O	O
31	3	in	IN	O	B-PP	O
31	4	the	DT	O	B-NP	O
31	5	near	IN	O	I-NP	O
31	6	future	JJ	O	I-NP	O
31	7	doctors	NNS	O	I-NP	B-ProfTitle
31	8	routinely	RB	O	O	B-Medical
31	9	will	MD	O	B-VP	O
31	10	use	VB	O	I-VP	O
31	11	several	JJ	O	B-NP	O
31	12	blood	NN	O	I-NP	O
31	13	tests	NNS	O	I-NP	O
31	14	to	TO	O	B-VP	O
31	15	help	VB	O	I-VP	O
31	16	diagnose	VB	O	I-VP	O
31	17	cancer	NN	O	B-NP	B-Medical
31	18	.	.	O	O	O

32	0	When	WRB	O	O	O
32	1	it	PRP	O	B-NP	O
32	2	was	VBD	O	B-VP	O
32	3	first	RB	O	O	B-Num
32	4	introduced	VBN	O	B-VP	O
32	5	in	IN	O	B-PP	O
32	6	1986	CD	O	B-NP	B-Date
32	7	COMMA	COMMA	O	O	O
32	8	the	DT	O	B-NP	O
32	9	PSA	NNP	O	I-NP	O
32	10	test	NN	O	I-NP	O
32	11	was	VBD	O	B-VP	O
32	12	designed	VBN	O	I-VP	O
32	13	to	TO	O	I-VP	O
32	14	help	VB	O	I-VP	O
32	15	doctors	NNS	O	B-NP	B-ProfTitle
32	16	monitor	VBP	O	B-VP	O
32	17	patients	NNS	O	B-NP	O
32	18	already	RB	O	B-VP	O
32	19	battling	VBG	O	I-VP	O
32	20	the	DT	O	B-NP	O
32	21	cancer	NN	O	I-NP	B-Medical
32	22	because	IN	O	O	O
32	23	a	DT	O	B-NP	O
32	24	climbing	VBG	O	I-NP	O
32	25	PSA	NNP	O	I-NP	O
32	26	typically	RB	O	O	O
32	27	signals	VBZ	O	B-VP	O
32	28	resurgent	JJ	O	B-NP	O
32	29	disease	NN	O	I-NP	B-Medical
32	30	and	CC	O	O	O
32	31	the	DT	O	O	O
32	32	need	VBP	O	B-VP	O
32	33	to	TO	O	I-VP	O
32	34	change	VB	O	I-VP	O
32	35	treatments	NNS	O	B-NP	O
32	36	.	.	O	O	O

33	0	By	IN	O	B-PP	O
33	1	the	DT	O	B-NP	O
33	2	early	JJ	O	I-NP	O
33	3	1990s	CD	O	I-NP	B-Date
33	4	COMMA	COMMA	O	O	O
33	5	doctors	NNS	O	B-NP	B-ProfTitle
33	6	were	VBD	O	B-VP	O
33	7	using	VBG	O	I-VP	O
33	8	the	DT	O	B-NP	O
33	9	test	NN	O	I-NP	O
33	10	COMMA	COMMA	O	O	O
33	11	along	IN	O	B-PP	O
33	12	with	IN	O	B-PP	O
33	13	a	DT	O	B-NP	O
33	14	DRE	NNP	O	I-NP	B-OrgCorp
33	15	COMMA	COMMA	O	O	O
33	16	to	TO	O	B-VP	O
33	17	diagnose	VB	O	I-VP	O
33	18	new	JJ	O	B-NP	O
33	19	prostate	NN	O	I-NP	B-Jour
33	20	cancer	NN	O	I-NP	B-Medical
33	21	cases	NNS	O	I-NP	O
33	22	COMMA	COMMA	O	O	O
33	23	and	CC	O	B-PP	O
33	24	by	IN	O	B-PP	O
33	25	1994	CD	O	B-NP	B-Date
33	26	the	DT	O	B-NP	O
33	27	Food	NNP	O	I-NP	B-Org
33	28	and	CC	O	I-NP	I-Org
33	29	Drug	NNP	O	I-NP	I-Org
33	30	Administration	NNP	O	I-NP	I-Org
33	31	gave	VBD	O	B-VP	O
33	32	its	PP$	O	B-NP	O
33	33	official	JJ	O	I-NP	O
33	34	stamp	NN	O	I-NP	O
33	35	of	IN	O	B-PP	O
33	36	approval	NN	O	B-NP	O
33	37	.	.	O	O	O

34	0	The	DT	O	B-NP	O
34	1	test	NN	O	I-NP	O
34	2	was	VBD	O	B-VP	O
34	3	developed	VBN	O	I-VP	O
34	4	by	IN	O	B-PP	O
34	5	scientists	NNS	O	B-NP	B-ProfTitle
34	6	led	VBD	O	B-VP	O
34	7	by	IN	O	B-PP	O
34	8	Catalona	NNP	O	B-NP	O
34	9	and	CC	O	I-NP	O
34	10	Dr.	NNP	O	I-NP	B-ProfTitle
34	11	Gerald	NNP	O	I-NP	B-Peop
34	12	Murphy	NNP	O	I-NP	I-Peop
34	13	of	IN	O	B-PP	O
34	14	the	DT	O	B-NP	O
34	15	Pacific	NNP	O	I-NP	O
34	16	Northwest	NNP	O	I-NP	O
34	17	Cancer	NNP	O	I-NP	O
34	18	Foundation	NNP	O	I-NP	O
34	19	.	.	O	O	O

35	0	At	IN	O	B-PP	O
35	1	the	DT	O	B-NP	O
35	2	time	NN	O	I-NP	O
35	3	COMMA	COMMA	O	O	O
35	4	both	DT	O	B-NP	O
35	5	were	VBD	O	B-VP	O
35	6	working	VBG	O	I-VP	O
35	7	at	IN	O	B-PP	O
35	8	the	DT	O	B-NP	O
35	9	Roswell	NNP	O	I-NP	B-Org
35	10	Park	NNP	O	I-NP	I-Org
35	11	Cancer	NNP	O	I-NP	I-Org
35	12	Institute	NNP	O	I-NP	I-Org
35	13	in	IN	O	B-PP	O
35	14	Buffalo	NNP	O	B-NP	B-LocCit
35	15	COMMA	COMMA	O	O	O
35	16	N.Y	NNP	O	B-NP	B-Loc
35	17	.	.	O	O	O

36	0	Managed	VBN	O	O	O
36	1	health	NN	O	B-NP	O
36	2	care	NN	O	I-NP	O
36	3	plans	NNS	O	I-NP	O
36	4	such	JJ	O	B-PP	O
36	5	as	IN	O	I-PP	O
36	6	health	NN	O	B-NP	O
36	7	maintenance	NN	O	I-NP	B-ProfTitle
36	8	organizations	NNS	O	I-NP	O
36	9	usually	RB	O	O	O
36	10	will	MD	O	B-VP	O
36	11	cover	VB	O	I-VP	O
36	12	the	DT	O	B-NP	O
36	13	$80	NN	O	I-NP	B-Money
36	14	blood	NN	O	I-NP	O
36	15	test	NN	O	I-NP	O
36	16	if	IN	O	O	O
36	17	the	DT	O	B-NP	O
36	18	patient	NN	O	I-NP	B-Medical
36	19	is	VBZ	O	B-VP	O
36	20	over	IN	O	B-PP	O
36	21	age	NN	O	B-NP	O
36	22	50	CD	O	I-NP	B-Num
36	23	COMMA	COMMA	O	O	O
36	24	or	CC	O	O	O
36	25	a	DT	O	B-NP	O
36	26	member	NN	O	I-NP	O
36	27	of	IN	O	B-PP	O
36	28	a	DT	O	B-NP	O
36	29	high-risk	JJ	O	I-NP	O
36	30	group	NN	O	I-NP	B-OrgCorp
36	31	COMMA	COMMA	O	O	O
36	32	such	JJ	O	B-PP	O
36	33	as	IN	O	I-PP	O
36	34	an	DT	O	B-NP	O
36	35	African	NNP	O	I-NP	B-LangRace
36	36	American	NNP	O	I-NP	I-LangRace
36	37	COMMA	COMMA	O	O	O
36	38	or	CC	O	O	O
36	39	has	VBZ	O	B-VP	O
36	40	a	DT	O	B-NP	O
36	41	strong	JJ	O	I-NP	O
36	42	family	NN	O	I-NP	O
36	43	history	NN	O	I-NP	O
36	44	of	IN	O	B-PP	O
36	45	prostate	NN	O	B-NP	B-Jour
36	46	cancer	NN	O	I-NP	B-Medical
36	47	.	.	O	O	O

37	0	It	PRP	O	B-NP	O
37	1	hasn	NN	O	B-NP	O
37	2	't	NN	O	I-NP	O
37	3	always	RB	O	O	O
37	4	been	VBN	O	O	O
37	5	this	DT	O	B-NP	O
37	6	way	NN	O	I-NP	O
37	7	.	.	O	O	O

38	0	A	DT	O	B-NP	O
38	1	prostate	NN	O	I-NP	B-Jour
38	2	cancer	NN	O	I-NP	B-Medical
38	3	advocacy	NN	O	I-NP	O
38	4	organization	NN	O	I-NP	O
38	5	COMMA	COMMA	O	O	O
38	6	the	DT	O	B-NP	O
38	7	Baltimore-based	JJ	O	I-NP	B-Org
38	8	American	NNP	O	I-NP	I-Org
38	9	Foundation	NNP	O	I-NP	I-Org
38	10	for	IN	O	B-PP	O
38	11	Urologic	NNP	O	B-NP	B-Peop
38	12	Disease	NNP	O	I-NP	I-Peop
38	13	COMMA	COMMA	O	O	O
38	14	is	VBZ	O	B-VP	O
38	15	going	VBG	O	I-VP	O
38	16	state-by-state	JJ	O	O	O
38	17	asking	VBG	O	O	O
38	18	lawmakers	NNS	O	B-NP	O
38	19	to	TO	O	B-VP	O
38	20	enact	VB	O	I-VP	O
38	21	legislation	NN	O	B-NP	O
38	22	requiring	VBG	O	B-VP	O
38	23	health-care	NN	O	B-NP	O
38	24	providers	NNS	O	I-NP	O
38	25	to	TO	O	B-VP	O
38	26	pay	VB	O	I-VP	O
38	27	for	IN	O	B-PP	O
38	28	PSA	NNP	O	B-NP	B-Org
38	29	tests	NNS	O	I-NP	I-Org
38	30	and	CC	O	O	O
38	31	DRE	NNP	O	B-NP	B-OrgCorp
38	32	exams	NNS	O	I-NP	O
38	33	.	.	O	O	O

39	0	Three	CD	O	B-NP	B-Num
39	1	years	NNS	O	I-NP	B-Date
39	2	ago	IN	O	O	O
39	3	COMMA	COMMA	O	O	O
39	4	only	RB	O	B-NP	O
39	5	three	CD	O	I-NP	B-Num
39	6	states	NNS	O	I-NP	O
39	7	had	VBD	O	B-VP	O
39	8	such	PDT	O	B-NP	O
39	9	a	DT	O	I-NP	O
39	10	requirement	NN	O	I-NP	O
39	11	.	.	O	O	O

40	0	Now	RB	O	O	O
40	1	15	CD	O	B-NP	B-Num
40	2	states	NNS	O	I-NP	O
40	3	do	VBP	O	B-VP	O
40	4	and	CC	O	O	O
40	5	more	RBR	O	O	O
40	6	are	VBP	O	B-VP	O
40	7	on	IN	O	B-PP	O
40	8	the	DT	O	B-NP	O
40	9	way	NN	O	I-NP	O
40	10	.	.	O	O	O

41	0	In	IN	O	B-PP	O
41	1	contrast	NN	O	B-NP	O
41	2	COMMA	COMMA	O	O	O
41	3	nearly	RB	O	B-NP	O
41	4	all	DT	O	I-NP	O
41	5	states	NNS	O	I-NP	O
41	6	require	VBP	O	B-VP	O
41	7	providers	NNS	O	B-NP	O
41	8	to	TO	O	B-VP	O
41	9	pay	VB	O	I-VP	O
41	10	for	IN	O	B-PP	O
41	11	annual	JJ	O	B-NP	O
41	12	mammograms	NNS	O	I-NP	O
41	13	.	.	O	O	O

42	0	``	``	O	O	O
42	1	It	PRP	O	B-NP	O
42	2	's	VBZ	O	B-VP	O
42	3	taken	VBN	O	I-VP	O
42	4	us	PRP	O	B-NP	O
42	5	one	CD	O	B-NP	B-Num
42	6	state	NN	O	I-NP	O
42	7	at	IN	O	B-PP	O
42	8	a	DT	O	B-NP	O
42	9	timeCOMMA	NN	O	I-NP	O
42	10	''	''	O	O	O
42	11	said	VBD	O	B-VP	O
42	12	M.	NNP	O	B-NP	O
42	13	Brooke	NNP	O	I-NP	B-Peop
42	14	Moran	NNP	O	I-NP	I-Peop
42	15	COMMA	COMMA	O	O	O
42	16	the	DT	O	B-NP	O
42	17	foundation	NN	O	I-NP	O
42	18	's	POS	O	B-NP	O
42	19	director	NN	O	I-NP	B-ProfTitle
42	20	of	IN	O	B-PP	O
42	21	government	NN	O	B-NP	O
42	22	affairs	NNS	O	I-NP	O
42	23	.	.	O	O	O

43	0	``	``	O	O	O
43	1	We	PRP	O	B-NP	O
43	2	are	VBP	O	B-VP	O
43	3	doing	VBG	O	I-VP	O
43	4	this	DT	O	B-NP	O
43	5	because	IN	O	O	O
43	6	some	DT	O	B-NP	O
43	7	men	NNS	O	I-NP	O
43	8	are	VBP	O	B-VP	O
43	9	having	VBG	O	I-VP	O
43	10	difficulty	NN	O	B-NP	O
43	11	getting	VBG	O	B-VP	O
43	12	the	DT	O	B-NP	O
43	13	tests	NNS	O	I-NP	O
43	14	.	.	O	O	O

44	0	What	WP	O	B-NP	O
44	1	we	PRP	O	B-NP	O
44	2	want	VBP	O	B-VP	O
44	3	is	VBZ	O	B-VP	O
44	4	for	IN	O	O	O
44	5	men	NNS	O	B-NP	O
44	6	not	RB	O	O	O
44	7	to	TO	O	B-VP	O
44	8	have	VB	O	I-VP	O
44	9	to	TO	O	I-VP	O
44	10	push	VB	O	I-VP	O
44	11	for	IN	O	B-PP	O
44	12	it	PRP	O	B-NP	O
44	13	.	.	O	O	O
44	14	''	''	O	O	O
